Among the various projects of this partnership, the team will participate in the global science education program “Discover the microbes inside!The Wolbachia Project”. This program allows middle and high school students, as well as high school students, to learn about arthropods (animals without backbones with an external chitin skeleton, segmented structure, and jointed legs, as well as insects, spiders, mites, and crustaceans) and to gather clinical knowledge about the bacterial endosymbiont (one organism that lives inside another to gain the advantages of both) Wolbachia pipientis.
It is estimated that this bacterium is found in approximately 50% of the world’s arthropods and has been shown, for example, to block the replication of potentially deadly RNA viruses, such as dengue virus, West Nile virus and Zika virus[1]. , is used to decrease the transmission of these and other viruses that are spread through the bite of inflamed arthropods (arboviruses) [2]. Because of those real-world impacts, Wolbachia is used as a style organism to examine the interactions between animals and microbes, genetics. , evolution, ecology and human health.
Microbiome studies aim to explore the relationships between microorganisms such as bacteria, fungi, and viruses, and their hosts. This may help to better understand the effect of the microbiome on health, disease, and ecological processes to expand new diagnostic responses. and healing strategies.
The primary task of Penn State’s Huck Institutes of Life Sciences One Health Microbiome Center (OHMC) will be for QIAGEN to provide tools and kits to prepare and process microbial samples.
QIAGEN’s comprehensive microbiome portfolio includes equipment for each and every facet of the clinical workflow, adding reliable pattern preparation kits optimized to read challenging environmental and human microbiome patterns. To ensure reproducibility, QIAGEN offers automated pattern preparation for standardization and reliability. The broad diversity of answers for the microbiome also includes downstream processing technologies such as NGS, virtual PCR (dPCR), or quantitative PCR (qPCR), all complemented by physically powerful bioinformatics equipment for seamless virtual analysis.
Learn more about QIAGEN’s solutions for microbiome research athttps://www.qiagen.com/us/applications/microbiome.
About QIAGEN
QIAGEN N. V. , a holding company founded in the Netherlands, is the world’s leading provider of Sample to Insight solutions that enable consumers to obtain valuable molecular data from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins. of blood, tissue and other materials. Testing technologies make these biomolecules visual and capable of being analyzed. Bioinformatics software and knowledge bases interpret knowledge to generate applicable and actionable knowledge. Automation responses attach them to seamless, cost-effective workflows. QIAGEN supplies answers to over 500,000 international consumers in the fields of molecular diagnostics (human health) and life sciences (university, R&R)
Penn State is a multi-campus, land-grant public university that educates scholars from around the world and American communities through integrated systems of training, scholarship and services. Penn State is an R1 university, a classification awarded through the Carnegie Foundation for the Advancement of Higher Education to America’s top educational institutions, achieving a record $1. 239 billion in educational spending this fiscal year 2022. 2023. The University’s interdisciplinary, collaborative and discovery-oriented studies and scholarship promote human and economic development, global understanding and the advancement of professional practice through the expansion of wisdom and its programs in herbal and implemented sciences, social sciences and behavior, engineering and technology. , arts and humanities, and an infinite number of professions. The University’s school project includes undergraduate, graduate, professional, continuing and extension education, presented through residential instruction and distance learning. Penn State’s educational systems are enriched by the talent, wisdom, diversity, creativity, and educational acumen of its faculty, scholars, and staff. As the only land-grant university in Pennsylvania, Penn State offers unprecedented access to education and public facilities to citizens of the Commonwealth and beyond. The University engages in collaborative activities with partners in the personal sector, education and governments around the world to generate, integrate, apply and disseminate knowledge valuable to society. For more information, stop by www. studies. psu. edu.
Forward-looking statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U. S. Securities Act of 1933, as amended, and Section 21E of the U. S. Securities Exchange Act. of 1934, as amended. to the extent that any of the statements contained herein relate to QIAGEN’s products, the addition of products used in the reaction to the COVID-19 pandemic, the launch and progression schedule, marketing approvals and/ or regulatory, monetary and operational prospects, expansion and expansion, collaborations, markets, strategy or operational effects, adding, without limitation, its expected adjusted net sales and adjusted diluted effectsArray are forward-looking, those statements are based on expectations and assumptions existing ones that involve a series of uncertainties and dangers. These uncertainties and hazards include, but are not limited to, hazards relevant to the management of expansion and foreign operations (adding the effects of currency fluctuations, regulatory processes and dependence on logistics), the variety of operational effects and distributions between categories of visitors, and the progression of advertising. markets for our consumer products in academic, pharmaceutical, deployed testing and molecular diagnostics; evolving relationships with consumers, suppliers and strategic partners; competence; immediate or unforeseen technological changes; fluctuations in demand for QIAGEN products (adding fluctuations due to general economic conditions, visitor funding levels and timing, budgets and otherwise); our ability to discharge regulatory approval of our products; difficulties in effectively adapting QIAGEN products for embedded responses and generating such products; QIAGEN’s ability to identify and expand new products and differentiate and protect our products from competitive products; market acceptance of QIAGEN’s new products and the integration of acquired technologies and businesses; government actions, global or regional economic progressions, weather or transportation delays, natural disasters, political or public health crises, adding the scale and duration of the COVID-19 pandemic and its effect on demand for our products and other aspects of our bussines. Array or other force majeure events; as well as the option that expected benefits similar to recent or pending acquisitions may not materialize as expected; and the other items discussed under “Risk Factors” contained in Item 3 of our recent maximum Annual Report on Form 20-F. For additional information, please see the discussions in the reports that QIAGEN has filed or provided to the United States Securities and Exchange Commission.
Source: QIAGEN N. V. Category: Corporate
[1] Flores, Heater, A. et O’Neill, Scott L. : “Control of vector-borne diseases through the release of modified mosquitoes,” Nature Reviews Microbiology, 2018. https://doi. org/10. 1038/s41579-018-0025 – 0[2] O’Neill, Scott L. et al. : “Large-scale deployment of Wolbachia in the network against dengue and other Aedes-borne arboviruses,” Gates Open Research, 2018. https:// doi. org/10. 12688 /puertasopenres. 12844. 1